Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “Global Fallopian Tube Cancer Therapeutics Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering. Array of strong drug…
AstraZeneca Tagrisso in a phase 3 trial, with previously-untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations, brought positive overall survival (OS) results.
Telix Pharmaceuticals and German Cancer Research Center (Deutsches Krebsforschungszentrum or DKFZ) have agreed to work together in the field of image-guided surgery for prostate cancer.
Study Met Its Co-Primary Endpoint of Overall Survival with Opdivo® (nivolumab) Plus Low Dose Yervoy® (ipilimumab) vs. Chemotherapy in First-Line Non-Small Cell Lung Cancer Patients Whose Tumors Express PD-L1 ≥1%
ImaginAb has started the clinical trial of its lead product, CD8 tracer Zr-Df-IAB22M2C, a first in class imaging agent that visualizes the immune system using non-invasive, whole-body in vivo PET imaging of CD8 T cells.
Immix Biopharma, said Tuesday it got a letter from the FDA authorizing it to expand its phase 1b/2a clinical trial of…
DUBLIN–(BUSINESS WIRE)–The “Cancer Monoclonal Antibodies Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s…
Syntrix Pharmaceuticals has started its Phase 1/2 clinical trial that will combine SX-682 with KEYTRUDA, Merck’s anti-PD-1 therapy, as it dosed the first patient, it said Thursday.
AstraZeneca and Merck revealed Wednesday that Lynparza (olaparib) has been approved in Japan as a maintenance treatment after 1st-line chemotherapy in patients with BRCA-mutated (BRCAm) advanced ovarian cancer, the only PARP inhibitor approved in Japan .
The KEYTRUDA breast cancer clinical development program encompassesseveral internal and external collaborative studies, including threeongoing registration-enabling studies in TNBC.